EP0568631A4 - Monoclonal antibodies to elam-1 and their uses. - Google Patents

Monoclonal antibodies to elam-1 and their uses.

Info

Publication number: EP0568631A4
Authority: EP; European Patent Office
Prior art keywords: elam; monoclonal antibodies; monoclonal; antibodies
Prior art date: 1991-01-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP92905123A

Other languages

German (de)

French (fr)

Other versions

EP0568631A1 (en

Inventor

Elisabeth Wayner

Mary L Phillips

Jeffrey L Winkelhake

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cytel Corp

Original Assignee

Cytel Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-24

Filing date

1992-01-23

Publication date

1995-04-05

1992-01-23 Application filed by Cytel Corp filed Critical Cytel Corp

1993-11-10 Publication of EP0568631A1 publication Critical patent/EP0568631A1/en

1995-04-05 Publication of EP0568631A4 publication Critical patent/EP0568631A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pain & Pain Management (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)

EP92905123A 1991-01-24 1992-01-23 Monoclonal antibodies to elam-1 and their uses. Withdrawn EP0568631A4 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US64587891A	1991-01-24	1991-01-24
US645878		1991-01-24
US73303391A	1991-07-22	1991-07-22
US733033		1991-07-22

Publications (2)

Publication Number	Publication Date
EP0568631A1 EP0568631A1 (en)	1993-11-10
EP0568631A4 true EP0568631A4 (en)	1995-04-05

Family

ID=27094802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP92905123A Withdrawn EP0568631A4 (en)	1991-01-24	1992-01-23	Monoclonal antibodies to elam-1 and their uses.

Country Status (11)

Country	Link
EP (1)	EP0568631A4 (en)
JP (1)	JPH06505253A (en)
AU (1)	AU1269092A (en)
CA (1)	CA2100681A1 (en)
IE (1)	IE920206A1 (en)
IL (1)	IL100764A0 (en)
NO (1)	NO932672L (en)
NZ (1)	NZ241399A (en)
OA (1)	OA09809A (en)
SK (1)	SK77393A3 (en)
WO (1)	WO1992012729A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5646123A (en) *	1991-06-10	1997-07-08	Alberta Research Council	Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US6004555A (en) *	1992-03-05	1999-12-21	Board Of Regents, The University Of Texas System	Methods for the specific coagulation of vasculature
US6036955A (en) *	1992-03-05	2000-03-14	The Scripps Research Institute	Kits and methods for the specific coagulation of vasculature
AU3737893A (en) *	1992-03-05	1993-10-05	Board Of Regents, The University Of Texas System	Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5660827A (en) *	1992-03-05	1997-08-26	Board Of Regents, The University Of Texas System	Antibodies that bind to endoglin
US5877289A (en) *	1992-03-05	1999-03-02	The Scripps Research Institute	Tissue factor compositions and ligands for the specific coagulation of vasculature
US5965132A (en) *	1992-03-05	1999-10-12	Board Of Regents, The University Of Texas System	Methods and compositions for targeting the vasculature of solid tumors
US6093399A (en) *	1992-03-05	2000-07-25	Board Of Regents, The University Of Texas System	Methods and compositions for the specific coagulation of vasculature
US6749853B1 (en)	1992-03-05	2004-06-15	Board Of Regents, The University Of Texas System	Combined methods and compositions for coagulation and tumor treatment
US5648458A (en) *	1992-05-06	1997-07-15	Affymax Technologies N.V.	Peptides and compounds that bind to ELAM-1
US5728802A (en) *	1992-05-06	1998-03-17	Affymax Technologies N.V.	Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en) *	1992-05-06	1997-07-01	Affymax Technologies N.V.	Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
EP0602290B1 (en) *	1992-12-04	1999-08-25	ConjuChem, Inc.	Antibody-conjugated Hepatitis B surface antigen and use thereof
US5723116A (en) *	1995-01-06	1998-03-03	University Of South Florida	Decreased mortality of severe acute pancreatitis following proximal cytokine blockade
AU6155896A (en) *	1995-06-07	1996-12-30	Cytel Corporation	Humanized antibodies to e-selectin
US6524553B2 (en)	1998-03-31	2003-02-25	Bristol-Myers Squibb Pharma Company	Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en)	1998-03-31	2003-03-25	Bristol-Myers Squibb Pharma Company	Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en)	1998-03-31	2003-04-15	Bristol-Myers Squibb Pharma Company	Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6818213B1 (en)	1998-07-13	2004-11-16	Board Of Regents, The University Of Texas System	Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US7067109B1 (en)	1998-07-13	2006-06-27	Board Of Regents, The University Of Texas System	Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
EP1140864A2 (en)	1998-12-18	2001-10-10	Du Pont Pharmaceuticals Company	Vitronectin receptor antagonist pharmaceuticals
EP1140204A2 (en)	1998-12-18	2001-10-10	Du Pont Pharmaceuticals Company	Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en)	1998-12-18	2004-09-21	Bristol-Myers Squibb Pharma Company	Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en)	1998-12-18	2003-05-27	Bristol-Myers Squibb Pharma Company	Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en)	1998-12-18	2003-01-28	Thomas D. Harris	Vitronectin receptor antagonist pharmaceuticals
US7030219B2 (en)	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
MX2011002250A (en) *	2008-08-25	2011-08-17	Amplimmune Inc	Pd-1 antagonists and methods of use thereof.
JP7185884B2 (en)	2017-05-02	2022-12-08	国立研究開発法人国立精神・神経医療研究センター	METHOD FOR PREDICTING AND DETERMINING THERAPEUTIC EFFECT OF IL-6 AND NEUTROPHIL-RELATED DISEASE
WO2019078344A1 (en) *	2017-10-20	2019-04-25	学校法人兵庫医科大学	Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
CN115190814A (en)	2020-01-24	2022-10-14	辉瑞公司	anti-E-selectin antibodies, compositions, and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990005786A1 (en) *	1988-11-14	1990-05-31	Brigham And Women's Hospital	Cloned genes which encode elam-1 and fusion proteins thereof, the protein products expressed therefrom, pharmaceutical compositions and the use thereof
WO1990013300A1 (en) *	1989-04-28	1990-11-15	Biogen, Inc.	ENDOTHELIAL CELL-LEUKOCYTE ADHESION MOLECULES (ELAMs) AND MOLECULES INVOLVED IN LEUKOCYTE ADHESION (MILAs)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0534944B1 (en) *	1988-11-14	1996-09-11	Brigham And Women's Hospital	Antibodies specific for elam-1 and the use thereof

1992
- 1992-01-23 AU AU12690/92A patent/AU1269092A/en not_active Abandoned
- 1992-01-23 IE IE020692A patent/IE920206A1/en not_active Application Discontinuation
- 1992-01-23 SK SK773-93A patent/SK77393A3/en unknown
- 1992-01-23 WO PCT/US1992/000577 patent/WO1992012729A1/en not_active Ceased
- 1992-01-23 JP JP4505427A patent/JPH06505253A/en active Pending
- 1992-01-23 CA CA002100681A patent/CA2100681A1/en not_active Abandoned
- 1992-01-23 EP EP92905123A patent/EP0568631A4/en not_active Withdrawn
- 1992-01-24 IL IL100764A patent/IL100764A0/en unknown
- 1992-01-24 NZ NZ241399A patent/NZ241399A/en unknown
1993
- 1993-07-22 OA OA60394A patent/OA09809A/en unknown
- 1993-07-23 NO NO93932672A patent/NO932672L/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990005786A1 (en) *	1988-11-14	1990-05-31	Brigham And Women's Hospital	Cloned genes which encode elam-1 and fusion proteins thereof, the protein products expressed therefrom, pharmaceutical compositions and the use thereof
WO1990013300A1 (en) *	1989-04-28	1990-11-15	Biogen, Inc.	ENDOTHELIAL CELL-LEUKOCYTE ADHESION MOLECULES (ELAMs) AND MOLECULES INVOLVED IN LEUKOCYTE ADHESION (MILAs)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C. BENJAMIN ET AL.: "A blocking monoclonal antibody to endothelial-leukocyte adhesion molecule-1 (ELAM1).", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 171, no. 1, 31 August 1990 (1990-08-31), DULUTH MN, USA, pages 348 - 353 *
M. BEVILACQUA ET AL.: "Identification of an inducible endothelial-leukocyte adhesion molecule.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 84, no. 24, December 1987 (1987-12-01), WASHINGTON DC, USA, pages 9238 - 9242 *
N. GRABER ET AL.: "T cells bind to cytokine-activated endothelial cells via a novel, inducible sialoglycoprotein and endothelial leukocyte adhesion molecule-1.", THE JOURNAL OF IMMUNOLOGY, vol. 145, no. 3, 1 August 1990 (1990-08-01), BALTIMORE MD, USA, pages 819 - 830 *
S. WELLICOME ET AL.: "A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1, or lipopolysaccharide.", THE JOURNAL OF IMMUNOLOGY, vol. 144, no. 7, 1 April 1990 (1990-04-01), BALTIMORE MD, USA, pages 2558 - 2565 *
See also references of WO9212729A1 *

Also Published As

Publication number	Publication date
NZ241399A (en)	1994-06-27
SK77393A3 (en)	1994-12-07
AU1269092A (en)	1992-08-27
IE920206A1 (en)	1992-07-29
CA2100681A1 (en)	1992-07-25
IL100764A0 (en)	1992-09-06
NO932672D0 (en)	1993-07-23
EP0568631A1 (en)	1993-11-10
NO932672L (en)	1993-09-23
OA09809A (en)	1994-04-15
JPH06505253A (en)	1994-06-16
WO1992012729A1 (en)	1992-08-06

Publication	Publication Date	Title
EP0568631A4 (en)	1995-04-05	Monoclonal antibodies to elam-1 and their uses.
IL101690A0 (en)	1992-12-30	Antibodies and methods utilizing the same
SG48420A1 (en)	1998-04-17	Humanized antibodies and uses thereof
EP0240344A3 (en)	1989-08-16	Monoclonal antibodies and their use
GB9412166D0 (en)	1994-08-10	Retargetting antibodies
EP0580859A4 (en)	1994-09-14	Anti-eda monoclonal antibody
GB8910395D0 (en)	1989-06-21	Human monoclonal antibody and hybridoma producing the same
EP0683675A4 (en)	1997-05-21	Human monoclonal antibodies to cytomegalovirus.
EP0506523A3 (en)	1993-10-20	Monoclonal antibodies
GB9204928D0 (en)	1992-04-22	Monoclonal antibody production
EP0267601A3 (en)	1988-10-12	Anti-pci monoclonal antibody
EP0562125A4 (en)	1994-03-18	Antibody composition.
GB2309459B (en)	1997-11-26	Antibodies to fungal antigens
EP0381763A4 (en)	1991-11-21	Antibody modified with toxin
ZA92468B (en)	1993-10-07	Monoclonal antibodies to ELAM-1 and their uses
GB8808586D0 (en)	1988-05-11	Monoclonal antibody to enteroviruses
GB9223676D0 (en)	1993-01-06	Modified antibodies
HU9503156D0 (en)	1996-01-29	Antibodies to p-selectin and their uses
EP0547631A3 (en)	1994-07-06	Antibody expression vector and antibodies produced thereby
EP0491351A3 (en)	1993-03-17	Chimeric antibodies and their use
IL103758A0 (en)	1993-04-04	Tumor specific monoclonal antibodies
GB8619905D0 (en)	1986-09-24	Monoclonal antibody
EP0668923A4 (en)	1996-06-26	Monoclonal antibody.
IE901210L (en)	1990-10-17	Monoclonal antibody
IE901956L (en)	1990-12-01	Monoclonal antibody.

Legal Events

Date	Code	Title	Description
1993-09-23	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1993-11-10	17P	Request for examination filed	Effective date: 19930813
1993-11-10	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL
1993-12-22	RBV	Designated contracting states (corrected)	Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
1995-03-29	RHK1	Main classification (correction)	Ipc: A61K 39/395
1995-04-05	A4	Supplementary search report drawn up and despatched	Effective date: 19950215
1995-04-05	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL
1997-05-28	17Q	First examination report despatched	Effective date: 19970411
1998-01-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
1998-03-04	18D	Application deemed to be withdrawn	Effective date: 19970822